Gossamer Bio, Inc. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf of investors who purchased Gossamer Bio, Inc. (NASDAQ: GOSS) common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer’s documents issued in connection with its February 8, 2019 initial public offering.
According to the Gossamer lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose: (1) the reasons for Gossamer’s GB001 trial failures; (2) the purported clinical validation of Novartis’ oral DP2 antagonist; and (3) that, as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.
“Gossamer Bio, Inc.”
If you suffered a loss in Gossamer you have until June 2, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.